Transcatheter aortic valve replacement (TAVR) has revolutionized the treatment of aortic stenosis, offering a less invasive alternative to surgical aortic valve replacement (SAVR). Initially reserved for high-risk and inoperable patients, TAVR has seen a rapid expansion in indications, including intermediate-risk and now low-risk populations. Recent clinical trials demonstrate the safety and efficacy of TAVR in low-risk patients, leading to shifts in clinical guidelines. This review explores the evolution of TAVR indications, focusing on its application in low-risk patients, clinical outcomes, and future directions.